Butanedioic acid, 2-[(4-fluorophenyl)methylene]-3-(phenylmethyl)- manufacturers
- IRG1-IN-1
-
- $99.00
-
2026-07-16
- CAS:2407652-42-8
- Purity: 99.69%
- Supply Ability: 10g
|
| | Butanedioic acid, 2-[(4-fluorophenyl)methylene]-3-(phenylmethyl)- Basic information |
| | Butanedioic acid, 2-[(4-fluorophenyl)methylene]-3-(phenylmethyl)- Chemical Properties |
| Boiling point | 508.3±50.0 °C(Predicted) | | density | 1.341±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | pka | 3.78±0.10(Predicted) | | form | Solid | | color | White to off-white |
| | Butanedioic acid, 2-[(4-fluorophenyl)methylene]-3-(phenylmethyl)- Usage And Synthesis |
| Uses | IRG1-IN-1 is an itaconic acid derivative. IRG1-IN-1 can inhibit immune-responsive gene 1 (IRG1) activity. IRG1-IN-1 can be used for the research of cancer, inflammation and autoimmune diseases[1]. | | in vivo | IRG1-IN-1 (compound 6) (i.p.; 0.2 mg/kg; 27 days) shows antitumor effect in C57BL/6 mice[1]. | Animal Model: | C57BL/6 mice[1] | | Dosage: | 0.2 mg/kg | | Administration: | IP; 27 days | | Result: | Increased survival of C57BL/6 mice bearing mouse CT26 colorectal tumors.
Decreased intratumoral frequency of M-MDSCs in tumors.
|
| | References | [1] Adonia Papathanassiu, et al. Compositions and methods of using itaconic acid derivatives. Patent. US20210261495A1. |
| | Butanedioic acid, 2-[(4-fluorophenyl)methylene]-3-(phenylmethyl)- Preparation Products And Raw materials |
|